Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 505

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

Open access
Serruys, Patrick W., García-García, Héctor M., Buszman, Pawel, Erne, Paul, Verheye, Stefan, Aschermann, Michael, Duckers, Henrikus, Bleie, Oyvind, Dudek, Dariusz, Bøtker, Hans Erik, von Birgelen, Clemens, D'Amico, Don, Hutchinson, Tammy, Zambanini, Andrew, Mastik, Frits, van Es, Gerrit-Anne, van der Steen, Antonius F.W., Vince, D. Geoffrey, Ganz, Peter, Hamm, Christian W., Wijns, William, Zalewski, Andrew · 2008 · Circulation

Abstract

Background— Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is expressed abundantly in the necrotic core of coronary lesions, and products of its enzymatic activity may contribute to inflammation and cell death, rendering plaque vulnerable to rupture. Methods and Results— This study compared the effects of 12 months of treatment with darapladib (an oral Lp-PLA 2 inhibitor, 160 mg daily) or placebo on coronary atheroma deformability (intravascular ultrasound palpography) and plasma high-sensitivity C-reactive protein in 330 patients with angiographically documented coronary disease. Secondary end points included changes in necrotic core size (intravascular ultrasound radiofrequency), atheroma size (intravascular ultrasound gray scale), and blood biomarkers. Background therapy was comparable between groups, with no difference in low-density lipoprotein cholesterol at 12 months (placebo, 88±34 mg/dL; darapladib, 84±31 mg/dL; P =0.37). In contrast, Lp-PLA 2 activity was inhibited by 59% with darapladib ( P <0.001 versus placebo). After 12 months, there were no significant differences between groups in plaque deformability ( P =0.22) or plasma high-sensitivity C-reactive protein ( P =0.35). In the placebo-treated group, however, necrotic core volume increased significantly (4.5±17.9 mm 3 ; P =0.009), whereas darapladib halted this increase (−0.5±13.9 mm 3 ; P =0.71), resulting in a significant treatment difference of −5.2 mm 3 ( P =0.012). These intraplaque compositional changes occurred without a significant treatment difference in total atheroma volume ( P =0.95). Conclusions— Despite adherence to a high level of standard-of-care treatment, the necrotic core continued to expand among patients receiving placebo. In contrast, Lp-PLA 2 inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability. These findings suggest that Lp-PLA 2 inhibition may represent a novel therapeutic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.108.771899

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 505

Metadata

Authors
Serruys, P. W., García-García, H. M., Buszman, P., Erne, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, O., Dudek, D., Bøtker, H. E., von Birgelen, C., D'Amico, D., Hutchinson, T., Zambanini, A., Mastik, F., van Es, G.-A., van der Steen, A. F. W., Vince, D. G., Ganz, P., Hamm, C. W., Wijns, W., & Zalewski, A.
Venue
Circulation
Published
2008-09-09
Volume
118
Issue
11
Pages
1172-1182
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2110551379
Cited by
505
References
26
FWCI
62.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.